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Abstract
Uveitis is a leading cause of blindness that presents a considerable challenge
given that our understanding of the mechanisms of disease is still evolving. Both
innate and adaptive immunity play a role in disease and mediators of these
responses can serve as therapeutic targets. TNF-α and IL-1β inflammatory cytokines
are central mediators of immunity and are involved in the dysregulated inflamma-
tory response during uveitis. Because toxicity limits the use of steroids and other
steroid-sparing agents, biologics that target a specific cell type or pathway are being
explored for the treatment of autoimmune uveitis. This chapter begins with a broad
overview of the aberrant immune response resulting in uveitis, and highlights key
mediators such as TNF-α, IL-1β, IL-6, and IL-17 and their potential use as thera-
peutic targets. Most biological agents discussed in this review have not been FDA-
approved for uveitis. However, favorable outcomes in early trials and FDA approval
of these drugs for the treatment of other autoimmune diseases associated with
uveitis support the potential for these biological agents in the management of
uveitis. This review aims to provide an updated report on the efficacy of biologics
that target TNF-α, IL-1β, IL-6, and IL-17 for the treatment of autoimmune uveitis.
Keywords: uveitis, TNF-α, IL-1β, IL-6, IL-17, etanercept, adalimumab, infliximab,
golimumab, certolizumab, anakinra, canakinumab, gevokizumab, rilonacept,
tocilizumab, sarilumab, secukinumab
1. Introduction
Uveitis is the third leading cause of blindness in western countries and fourth
worldwide [1, 2]. The ocular inflammation associated with uveitis can occur in
every tissue within the eye so is frequently described according to the anatomical
location of the inflammation [3, 4]. Anterior uveitis includes inflammation of the
iris, ciliary body, and anterior chamber. Intermediate uveitis involves the vitreous
and pars plana, while posterior uveitis describes inflammation of the retina and
choroid [5, 6]. Sometimes, both anterior or intermediate and posterior uveitides can
occur, which is referred to as panuveitis [5, 6]. Uveitis can be due to infectious or
noninfectious causes; the latter is thought to be immune mediated and is commonly
referred to as autoimmune uveitis (AU) [7, 8]. Both infectious and noninfectious
uveitides lead to damaging inflammation, and undertreatment leads to destruction
of ocular tissue which can result in vision loss [9, 10]. So, the goal of treatment is
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to suppress the ocular inflammation to preserve vision [7]. Generally, uveitis of
infectious origin is treated with systemic and/or local antibiotics, antivirals, or
antifungals, and inflammation usually resolves once the pathogen is eliminated [7].
Because noninfectious uveitis is immune-mediated, suppression of the immune
system is necessary [7, 11].
The current treatment paradigm for noninfectious uveitis is to treat with medi-
cations that suppress the immune system to drive the inflammatory response into
remission [2, 7]. Corticosteroids can be given locally and/or systemically to rapidly
suppress inflammation, but they are not a long-term treatment option due to their
side effects [7, 12–14]. When the steroids are discontinued, there is a risk of
recurrent disease [15]. Localized slow-releasing steroid implants have been deve-
loped and have shown some efficacy, but these can result in cataract and glaucoma
[14, 16]. As such, immunomodulating or immunosuppressants are used concomi-
tantly to supplement or taper off the steroids in severe or chronic cases [7]. These
immunosuppressive therapies, also called “steroid-sparing drugs,” include non-
steroidal anti-inflammatory drugs (NSAIDs); antimetabolites such as methotrexate,
azathioprine, and mycophenolate; T-cell inhibitors such as tacrolimus; and
cyclosporine and mTOR inhibitors such as rapamycin and derivatives of rapamycin
[2, 7]. Also, DNA alkylating agents such as chlorambucil and cyclophosphamide can
also be utilized. The steroid-sparing drugs have significantly improved the outcome
of uveitis and provide additional more targeted treatment options [17]. However, as
with steroids, these drugs may produce significant side effects, including an
increased susceptibility to infection, and many still fail to provide lasting remission
[2, 18]. It is conceivable that a targeted therapy that only suppresses one or two
inflammatory pathways may offer a more favorable side effect profile than standard
steroid-sparing agents [2]. Biologics are a relatively new class of medications that
specifically target specific molecules involved in inflammation. The major hurdles
to implement biological therapies include a large financial burden and questions
about long-term efficacy. Therefore, in this report we discuss the outcomes of
treating uveitis with biologics with a specific focus on inhibition of TNF-α, IL-1β,
IL-6, and IL-17 inflammatory cytokines.
1.1 Biologics in uveitis
Progress in the field of ocular immunology has provided a basic understanding
of the inflammatory mechanisms that contribute to the pathogenesis of
noninfectious uveitis. This allows for a better understanding of the mechanism of
action of many medications. Many of the current immunosuppressive therapies
suppress inflammation via broad mechanisms of action. For example,
mycophenolate inhibits expansion and survival of lymphocytes by limiting the
transport of purines into the cell, thus preventing proliferation of T cells and B cells
which are dependent on extracellular purines [19]. The disadvantage of this strategy
is that differentiation of regulatory T cells (Tregs), a subset of T cells, that have
been demonstrated to suppress autoimmune disease would also be inhibited
[20, 21]. Rapamycin inhibition of mTOR is effective in suppressing rapidly dividing
cells such as leukocytes, but the mTOR pathway is utilized by many cells in the
body, so mTOR inhibitors are associated with a wide array of side effects [22].
Therefore, the effective treatment of autoimmune uveitis with a minimal side effect
is dependent on the development of much more targeted treatments.
A better understanding of autoimmune diseases and specifically of ocular
immunology now provides the possibility of specifically targeting important
inflammatory pathways rather than broadly suppressing the immune response [14].
One such method to target specific inflammatory cytokines or receptors is with the
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use of biologics [2, 14, 23]. The biological agents, also called “biological response
modifiers” or “biologics,” are a broad group of molecules that have been utilized to
interfere and alter inflammation during immune-mediated processes [2]. These
agents include recombinant cytokines, monoclonal antibodies that target cell sur-
face proteins and receptors, specific antagonists of cytokines, and soluble receptors
[14, 24]. These drugs function by specifically suppressing a single pathway through
targeting of an effector molecule [14, 23]. As such, biological agents are being used
as a treatment for refractory uveitis [25, 26]. Unfortunately, biologics are not always
an option because of extremely high costs that limit approval for off-label use by
insurance. The justification to insurance can be even more challenging because of
the limited number of published reports documenting the effectiveness of biologics.
As such, it is necessary to demonstrate that current biologics are effective in
providing sustained remission. Therefore, the purpose of this review is to provide a
summary of the literature of the outcomes and effectiveness of biologics that target
the key inflammatory mediators especially TNF-α, IL-1β, IL-6, and IL-17. In
addition, in order to provide a better understanding of the immunological function
of these biologics, we will also provide a limited discussion of the immunological
pathways that are targeted by TNF-α, IL-1β, IL-6, and IL-17.
1.2 Basic immunology of uveitis
Immune-mediated or autoimmune uveitis is a group of heterogeneous diseases
that can be restricted to the eye, as in pars planitis or birdshot chorioretinopathy.
The vast majority of uveitis patients experience localized inflammation. However,
ocular inflammation can also be associated with systemic disease, such as in lupus,
ankylosing spondylitis, and multiple sclerosis [27]. There are still many unknown
aspects of the pathogenesis of autoimmune uveitis, but results from human and
animal research supported potential mechanisms. One theory is the molecular
mimicry model, in which the manifestation of autoimmune uveitis is thought to
result from clearance of a pathogen with an antigen with a similar structure to a
self-antigen in the eye [28–30]. However, the initiating antigens have not been
isolated nor is it likely to be identified due to antigenic shift that occurs with chronic
tissue inflammation [31]. In some cases, there is a genetic component, as evidenced
with gene associations mapping to the HLA locus, such as HLA-B27, HLA-A29, and
HLA-B51 [32–34]. HLA-B27 is associated with anterior uveitis, reactive/rheumatoid
arthritis, and ankylosing spondylitis. HLA-A29 is associated with birdshot
chorioretinopathy, and HLA-B51 is associated with Behcet’s disease [35–37].
Because there is not 100% penetrance with these HLA alleles, there is likely also an
environmental trigger that is required as well. This demonstrates the heterogeneity
associated with autoimmune uveitis and illustrates why a single therapy may not be
effective for all uveitis patients. Thus, additional research is necessary to further our
understanding of this disease.
Innate and adaptive immune cells are intricately connected during a normal
immune response and aberrant responses as in autoimmune uveitis [30, 38]. The
trigger of immune activation during uveitis is not well understood, but it is specu-
lated that both environmental and genetic predispositions can initiate an inflam-
matory response that would eventually cause damage to the eye during uveitis
[39, 40]. Innate immune cells such as monocytes, macrophages, and dendritic cells
generally respond first to these inflammatory cues [41, 42]. These activated innate
immune cells secrete proinflammatory cytokines such as TNF-α, IL-6, and IL-1β
which serve as mediators of inflammation [34, 38, 43]. The role of innate immunity
in the pathogenesis of uveitis is evident in both human and animal studies, where
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markers of inflammatory monocytes are more abundant in uveitis patients than
their healthy controls [44]. Likewise, high levels of these inflammatory cytokines
have been shown to be elevated in the ocular fluids of uveitis patients [45]. Also,
animal models of uveitis which recapitulate the pathologies seen in human uveitis
require adjuvants in the induction of the T-cell-mediated uveitis [46]. These
required adjuvants activate the pattern recognition receptors (PRR) on innate
immune cells that result in the production of these TNF-α, IL-1β, and IL-6 [34, 38].
As such, inhibition of TNF-α, IL-1β, and IL-6 is effective in reducing the ocular
inflammation observed in numerous mouse models of uveitis [47–49]. Activated
innate immune cells can act as antigen-presenting cells (APCs) and/or cytokine-
secreting cells to provide signals that activate B and T cells [50]. In response to this
activation, T cells differentiate into effector cells and largely produce inflammatory
mediators such as cytokines that activate and recruit other immune cells that
enhance ocular damage [34].
Several studies have highlighted the involvement of mediators and cellular
responses that integrate both innate and adaptive immunities in the pathogenesis of
uveitis [30, 41]. In this review, TNF-α, IL-17, IL-6, and IL-1β are the mediators of
interest. While TNF-α, IL-6, and IL-1β are central mediators of inflammation that
lead to activation of both innate and adaptive immunities, IL-17 is produced by a
specific effector T cells (Th17 cells) that has a strong association with autoimmunity
[51, 52]. Elevated levels of these cytokines are seen in the ocular fluids and plasma
of uveitis patients [53–55].
Biological agents that specifically target these immune mediators or
T-cell-activating molecules have gained wide recognition as effective therapy
for immune-mediated diseases such as rheumatoid arthritis (RA), juvenile idio-
pathic arthritis (JIA), psoriasis, sarcoidosis, and organ rejection and are there-
fore being used for the treatment of uveitis [56]. Results from treatment of
animal models and biological samples of uveitis patients with antagonists of the
inflammatory mediators have demonstrated the involvement of these mediators
with autoimmune uveitis [57, 58]. Currently, there are numerous clinical trials
that are testing the efficacies of biological agents for the treatment of autoim-
mune uveitis.
2. TNF-α inhibitors
TNF-α inhibitors are biological agents that target tumor necrosis factor alpha
(TNF-α) and its receptors. TNF-α was initially studied for its ability to stimulate
necrosis of malignant tumors [59, 60]. An immunological role was later
discovered as it is also an important inflammatory mediator [59, 60]. TNF-α is a
proinflammatory cytokine that is secreted by many immune cells of the innate and
adaptive arm of the immune response, including T cells, and macrophages, and
nonimmune cells such as keratinocytes [60]. TNF-α binding to one of the two
isoforms of its transmembrane receptor (TNFr1 and TNFr2) is the first step in
triggering a response [59]. Binding of TNF ligand to its receptor activates down-
stream signals that lead to a cascade of cellular events that include cellular prolif-
eration, differentiation, apoptosis, survival, and regulation of inflammatory
cytokine production [60]. Because these events lead to activation of inflammatory
cells, TNF-α is considered a master regulator of inflammation [60, 61]. TNF-α has
been implicated in the pathogenesis of autoimmune uveitis and other immune-
mediated diseases especially organ-specific diseases [62–64]. High levels of TNF-α
have been reported in the aqueous humor and sera of uveitis patients compared to
their healthy controls [65]. Also, elevated levels of this cytokine are observed in
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the animal models of autoimmune uveitis, and inhibition of TNF-α activity results
in disease remission in these animal models [47, 66]. Involvement of TNF-α in
many autoimmune diseases has made it a therapeutic target [60]. Currently, there
are numerous biologics that target TNF-α activity; these include infliximab,
etanercept, adalimumab, golimumab, and certolizumab [67]. Biologics that target
TNF-α and its interaction with its receptors were developed and approved for the
treatment of autoimmune diseases such as RA, psoriasis, sarcoidosis, inflamma-
tory bowel disease, etc. [67]. The efficacy of TNF-α inhibitors in the treatment of
these diseases has led to great interest in the use of these biological agents for the
treatment of uveitis.
2.1 Etanercept
Etanercept is a recombinant fusion protein that contains the extracellular ligand-
binding portion of the human TNF receptor (TNFr2) and the Fc portion of human
IgG1 [68]. Because the structure of etanercept contains no membrane-bound
portion, it is essentially a soluble TNF receptor that binds the free form of all TNF
isoforms (TNF-α, TNF-β, and TNF-γ) [68]. Because the soluble form of TNF and
membrane-bound TNF have opposing immunological effects, it is of note that
etanercept does not bind to the membrane-bound form [69].
For two decades, etanercept has been used to treat rheumatic diseases, and it is
FDA approved for the treatment of JIA, RA, ankylosing spondylitis (AS), psoriatic
arthritis (PA), and plaque psoriasis (PP) [68, 70]. Effectiveness of etanercept in the
treatment of these diseases led to interest in the use of this drug for uveitis.
Etanercept has been reported to be a treatment for refractory uveitis in pediatric
patients [71]. In the prospective study, beneficial effects of etanercept were
observed in at least 63% of the patients after 3 months of treatment [71]. Another
prospective study of the efficacy of etanercept in patients with JIA-associated
uveitis showed 73% of the patients had an initial response after 3 months of treat-
ment; however, only about half of the responders (39%) remained in remission
after 1 year [72]. In addition, several prospective and retrospective studies of
etanercept did not show treatment efficacy in uveitis associated with systemic
diseases such as JIA [73], sarcoidosis [74], or chronic uveitis [75]. Some studies have
shown an increased incidence of uveitis in patients treated with etanercept for
ankylosing spondylitis [76–78]. In general, the efficacy of etanercept for uveitis is
poor, and several studies have shown that other TNF inhibitors (adalimumab and
infliximab) are more effective and preferred for the treatment of uveitis as
discussed below [79, 80].
Administration and dosing: Enbrel (Immunex, Thousand Oaks, CA) is the brand
name for etanercept, and it is typically administered subcutaneously at a dose of
50 mg every 1–2 weeks or 0.8 mg/kg weekly. It was first approved by the FDA in
1998 for the treatment of rheumatic diseases.
Adverse effects: Side effects of etanercept can include localized effects such as
pain and swelling at the injection site [81]. There are reported cases of an increased
risk of fungal infection and TB reactivation [78, 82]. Some reports have shown
exacerbation of uveitis or development of uveitis concurrent with etanercept treat-
ment [78, 82]. Other serious side effects include lupus-like disease due to autoanti-
bodies generated against etanercept, exacerbation of the central and peripheral
nervous system demyelinating disorders, hematologic, and cardiovascular side
effects [81, 83, 84]. Please see full prescribing information for complete list.
Contraindications: Sepsis [85]. Tuberculosis reactivation or newly acquired
tuberculosis has been reported to have an increased incidence in patients on TNF
inhibitors [86, 87]; additional discussion is provided at the end of this section.
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2.2 Adalimumab
Adalimumab was the first fully human IgG1 monoclonal antibody to be approved
by the FDA. It was approved as an antibody against TNF-α following the develop-
ment of infliximab and etanercept. Adalimumab inhibits TNF-α activity by directly
binding TNF-α to prevent it from interacting with TNF receptors [88]. Adalimumab
is FDA approved for the treatment of RA, inflammatory bowel disease, PA, JIA, and
AS [89]. Several prospective and retrospective studies report the efficacy of
adalimumab in the treatment of uveitis. In a prospective VISUAL I and VISUAL II
study (2010 to 2015) of 217 and 226 adult patients with active and inactive uveitis,
respectively, Sheppard et al. found significant improvement in clinical outcomes in
patients treated with adalimumab compared to the placebo group [90]. Also, a
prospective study from 2006 to 2011 showed that 17 out of 19 adult patients with
refractory uveitis in Behcet’s disease achieved clinical improvement [91]. Similar
results were observed in another prospective study with 72 adult patients conducted
between 2006 and 2012 [92]. This study reported that adalimumab reduced the
frequency of uveitis attacks in patients with AS by 72% [92]. Another prospective
study with 31 refractory uveitis patients reported 68% of these patients showed
resolution of ocular inflammation at 10 weeks of treatment and after 1 year 39% of
these patients maintained remission [93]. Similarly, in a retrospective study, the
efficacy and safety of adalimumab in Behcet’s disease-related uveitis were reported
using records of 40 patients treated with adalimumab for up to 12 months [94]. The
retrospective chart review showed remission was achieved in 95% of the patients
[94]. The use of adalimumab in pediatric patients was reported in a prospective study
with 18 young patients (2–19 years) with chronic anterior uveitis; 88% of the patients
responded to the therapy [95]. Similar results were reported in another pediatric
study including 90 children and adolescents; this study shows responsiveness to
adalimumab and lower treatment failure compared to a placebo treatment [96].
In 2014, the executive committee of the American Uveitis Society recommended
adalimumab as a first-line treatment for uveitis associated with Behcet’s disease
when uncontrolled by standard immunomodulatory drugs [24]. Importantly, in
2016, adalimumab became the first and the only drug to be FDA approved for the
treatment of intermediate, posterior, and panuveitis [97].
Administration and dosing: Adalimumab is sold under the brand name Humira
(AbbVie Inc., North Chicago, IL), and Amjevita is a biosimilar (Amgen, Inc.,
Thousand Oaks, CA), but Amjevita is not available in the USA due to patent issues,
and it is typically given subcutaneously every 1–2 weeks at a dose of 40–80 mg or
20 mg if the body weight is less than 30 kg.
Adverse effects: In some of the studies mentioned above, adalimumab treatment
for uveitis was associated with some severe side effects. These serious side effects
include sarcoidosis, anaphylaxis, optic neuritis, Guillain-Barre syndrome, multiple
sclerosis, adenoma, and melanoma [83, 91, 98–100]. Please see full prescribing
information for complete list.
Contraindications: None are listed with the FDA [101]. Tuberculosis reactivation
or newly acquired tuberculosis has been reported to have an increased incidence in
patients on TNF inhibitors [86, 87]; additional discussion is provided at the end of
this section.
2.3 Infliximab
Infliximab is a chimeric IgG1 monoclonal antibody that contains the human
constant region and murine variable regions, and it binds both membrane-bound
and free TNF-α [102]. This drug was initially developed and approved by the FDA
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in 1998 for the treatment of inflammatory bowel disease; subsequently, this drug
was approved for the treatment of RA and other rheumatoid diseases [103, 104].
Clinical trials to assess the efficacy of infliximab as a treatment for uveitis demon-
strate that it is a potential treatment option. One prospective study reported a rapid
response to infliximab in six adult patients that had uveitis associated with Behcet’s
disease or sarcoidosis [105]. Similarly, in another prospective study, 9 out of 11
patients with refractory posterior uveitis showed improvement of disease following
treatment with infliximab [106]. Efficacy of infliximab in pediatric patients with
uveitis has been demonstrated in retrospective studies of JIA patients [107, 108]. All
17 patients in one study showed a rapid and well-tolerated response to infliximab
[108]. Also, several studies have demonstrated the effectiveness of infliximab in
localized uveitis as well as systemic autoimmune diseases associated with uveitis.
One prospective study demonstrated effective suppression of uveitis in 18 out of 23
patients at 10 weeks of treatment initiation, and clinical success was achieved in all
patients at week 50 [109].
Numerous clinical trials have compared the efficacy between adalimumab and
infliximab in the treatment of noninfectious uveitis; most of these studies
concluded that, overall, both anti-TNF-α agents showed equivalent efficacies. In
one study, 160 patients with refractory uveitis were treated with either infliximab
or adalimumab, 93% of the patients achieved remission after 12 months of treat-
ment, and no significant difference in terms of occurrence of uveitis was seen
between the two treatment groups [110]. Also, the expert panel from the American
Uveitis Society recommends infliximab or adalimumab as the first-line treatment
for uveitis in Behcet’s disease [24].
Administration and dosing: Infliximab is sold under the brand name Remicade
(Janssen Biotech, Horsham, PA) and is typically given intravenously at a dose of
3–5 mg/kg at weeks 0, 2, 6, and subsequently every 8 weeks [24].
Adverse effects: The most notable side effect of infliximab in some patients was
generation of autoantibody against the non-humanized component of the drug
[111]. Other serious side effects include an increased risk of lymphoma, reactivation
of TB, and an increased risk of fungal infections [82]. Infliximab may also contri-
bute to the exacerbation of demyelinating diseases and is not preferred in patients
with multiple sclerosis [112, 113]. Please see full prescribing information for
complete list.
Contraindications: Heart failure has been reported with doses greater than 5 mg/
kg. Severe hypersensitivity to Remicade or to inactive components of Remicade or
to proteins of mouse origin has been reported [114]. Tuberculosis reactivation or
newly acquired tuberculosis has been reported to have an increased incidence in
patients on TNF inhibitors [86, 87]; additional discussion is provided at the end of
this section.
2.4 Golimumab
Golimumab is a promising TNF-α inhibitor for the treatment of autoimmune
uveitis. It is a fully humanized IgG1 monoclonal antibody that binds to both soluble
and membrane-bound TNF-α. This antibody has greater TNF-α binding affinity
than infliximab and adalimumab [115]. This drug was FDA approved for the treat-
ment of ulcerative colitis, RA, PA, and AS in 2013 [116]. The success of other TNF-α
inhibitors (adalimumab and infliximab) in the treatment of uveitis paved way for
the use of golimumab in uveitis [117]. Retrospective and prospective studies of
golimumab in uveitis showed promising results of its effectiveness in maintaining
remission. Retrospective analysis of the efficacy of golimumab in patients with
recurrent uveitis between 2013 and 2015 showed remission achieved in 12 eyes
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out of 15 after a median follow-up period of 11 months [118]. A prospective study
of 15 patients with refractory uveitis related with spondyloarthritis demonstrated
the effectiveness of golimumab in uveitis. The results from this study showed
rapid improvement of intraocular inflammation in most of the patients with
chronic or relapsing uveitis including patients that were refractory to other TNF-α
inhibitors [119].
Administration and dosing: Golimumab is marketed under the brand name
Simponi (Janssen Biotech, Horsham, PA) and is given subcutaneously at a dose of
50 mg once a month or 200 mg then 100 mg at week 2 and 100 mg every 4 weeks
for UC. It can be given intravenously at a dose of 2 mg/kg at week 0 and 4 and then
every 8 weeks.
Adverse effects: Golimumab as with other TNF-α inhibitors interferes with the
inflammatory response, so the use of this drug is associated with side effects
similar to those seen in other TNF-α, specifically increased risk of bacterial
infections and reactivation of TB [120–122]. When golimumab is combined with
antimetabolites such as azathioprine or 6-mercaptopurine, it can lead to an
increased risk of malignancies [123]. Please see full prescribing information for
complete list.
Contraindications: None are listed with the FDA [124]. Tuberculosis reactivation
or newly acquired tuberculosis has been reported to have an increased incidence in
patients on TNF inhibitors [86, 87]; additional discussion is provided at the end of
this section.
2.5 Certolizumab
Certolizumab is a member of the TNF-α inhibitors that was developed and
approved by the FDA for the treatment of Crohn’s disease and RA in 2008 and
2009, respectively [125]. Certolizumab pegol is a humanized antigen-binding
fragment (Fab) of monoclonal antibody that targets TNF-α and lacks the Fc region.
The Fab fragment is conjugated to polyethylene glycol to increase the half-life of
certolizumab compared to other TNF inhibitors [2]. Interest in effectiveness of
certolizumab in the treatment of uveitis occurred as an indirect consequence of
treatment of systemic diseases associated with uveitis [126]. A retrospective study
reported the effectiveness of certolizumab in uveitis, which highlighted the efficacy
of certolizumab in five of seven patients with uveitis refractory to other anti-TNF-α
agents [126]. Prospective studies are ongoing to test the efficacy of certolizumab in
anterior uveitis (NCT03020992 clinicaltrials.gov).
Administration and dosing: Certolizumab is marketed under the trade name
Cimzia (UCB, Brussels, Belgium). It is administered subcutaneously at a dose of
400 mg at weeks 0, 2, and 4 and then 200–400 mg every 4 weeks.
Adverse effects: Studies of the effectiveness of certolizumab in the treatment of
autoimmune diseases including uveitis have recorded serious side effects that
include new-onset uveitis [127, 128]. Others have observed worsening of arthritis
symptoms following treatment with certolizumab. Other serious side effects
include increase risk of infection, lupus-like syndrome, and cancer [129]. Please see
full prescribing information for complete list.
Contraindications: Serious hypersensitivity reaction to certolizumab pegol or the
inactive components has been reported [130]. Tuberculosis reactivation or newly
acquired tuberculosis has been reported to have an increased incidence in patients
on TNF inhibitors [86, 87]; additional discussion is provided at the end of this
section.
TNF inhibitors suppress the signals that occur early in the inflammatory
cascade and with the exception of etanercept have produced remarkable
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outcomes in uveitis. Currently, adalimumab and infliximab have been shown to
be effective in the treatment of refractory uveitis especially in Behcet’s disease-
related uveitis or JIA. However, only adalimumab is approved by the FDA for
the treatment of uveitis. Because uveitis has occurred in patients being treated
with etanercept for autoimmune disease, it is not recommended for the treat-
ment of uveitis [127]. The reactivation of latent tuberculosis or newly acquired
tuberculosis is not listed as a contraindication by the FDA, but there are multi-
ple reports that the incidence of tuberculosis reactivation or newly acquired
infection is greater in patients on TNF inhibitor therapy [86, 87]. As such,
tuberculosis screening before initiation of TNF inhibitor therapy and routine
screening for tuberculosis are highly recommended. Additional clinical outcome
data from large population studies will be required to demonstrate the safety
and efficacy of golimumab and certolizumab. The effectiveness and utilization
of TNF-α inhibitors in the treatment of uveitis are limited by the huge cost of
these drugs, limited outcome data on clinical use of TNF-α inhibitors in some
disease-specific uveitis, and severe side effects in some cases.
3. IL-1 inhibitors
The biological agents classified as IL-1 inhibitors target and inhibit the
proinflammatory cytokine, IL-1β, and its receptor, IL-1R. IL-1 is a strong
proinflammatory cytokine that plays a role in both local and systemic immune
responses and is also involved in tissue damage during chronic inflammation
[131, 132]. IL-1 mediates its inflammatory response through IL-1α and IL-1β. The
latter has been reported to be a critical mediator of autoimmunity when compared
with IL-1α [133]. IL-1β is secreted by innate immune cells such as macrophages,
neutrophils, dendritic cells, and vascular endothelial cells [55]. IL-1β signals through
the IL-1 receptor (IL-1R) to produce its inflammatory effects such as differentiation
and expansion of antigen-specific T cells, cell maturation, and induction of acute-
phase reaction [134]. This cytokine signaling is known to play a role in autoimmune
diseases as demonstrated clinically with significantly elevated levels of IL-1β in
biological samples including tears of uveitis patients compared to healthy controls
[135]. Also, high levels of this cytokine are implicated in some systemic autoim-
mune diseases including those associated with uveitis [131].
Studies have shown that loss of IL-1 signaling provides protection from uveitis
in animal models of autoimmune uveitis [131]. Being a pleiotropic cytokine, IL-1
activity is tightly regulated by a naturally occurring antagonist of IL-1 receptor
(IL-1RA) which specifically inhibits the activities of IL-1 cytokines through
blockade of IL-1 receptor. Under physiologic conditions, balance exists between
the specific receptor antagonist and IL-1. However, imbalance in the levels of IL-
1 and/or IL-1 RA can increase the risk of developing immune-mediated diseases
[136]. Also, exogenous administration of IL-1RA in animal models showed inhi-
bition of IL-1 signaling events [136]. Biological agents such as recombinant IL-1R
antagonist (anakinra) which mimics the activity of IL-RA have been developed
and have shown great success in the reduction of autoimmune diseases [137, 138].
Other biological agents such as soluble decoy IL-1 receptor (rilonacept) and
neutralizing monoclonal antibodies (canakinumab and gevokizumab) that have
specific inhibition of IL-1 activity have also been utilized in the treatment of
autoimmune diseases. Suppression of ocular inflammation may be achieved due
to the efficacy of IL-1β inhibitors in the control of inflammation in systemic
autoimmune diseases that are associated with uveitis. Additional discussion of
these inhibitors is provided below.
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3.1 Anakinra
Anakinra was first introduced in 1993 (Kineret, Amgen Inc., Thousand Oaks,
California), and it is a recombinant non-glycosylated human IL-1RA. It was first
approved for the treatment of RA and neonatal-onset multisystem inflammatory
disease (NOMID) by the FDA in 2001 [139]. There is limited data on the use of
anakinra in the treatment of uveitis; however, a few case studies have reported its
effectiveness in uveitis. One study looked at its effect as a treatment for NOMID,
which is associated with childhood uveitis; anakinra produced resolution of ocular
symptoms in addition to the systemic disease improvement. In this case study, a
4-year-old with chronic infantile neurological cutaneous articular (CINCA)
syndrome that is associated with uveitis, who had a poor response to TNF-α inhibi-
tors, showed a significant sustained improvement with anakinra [140]. Another
case series also demonstrated the effectiveness of anakinra in two patients with
anterior uveitis due to exposure to etanercept or uveitis refractory to infliximab
[141]. Also, a retrospective study of 19 patients with Behcet’s disease-related uveitis
showed effective control of inflammation and improvement in ocular symptoms
after 12 months of treatment with anakinra [142].
Administration and dosing: Anakinra is sold under the brand name Kineret
(Swedish Orphan Biovitrum Stockholm, Sweden) and is given subcutaneously at a
dose of 100 mg daily or up to 8 mg/kg a day.
Adverse effects: Anakinra is associated with side effect that ranges from a local
reaction at the injection site to more severe side effects such as hepatitis, neutrope-
nia, and increase risk of infection [143–145]. Another side effect that could occur is
the generation of autoantibodies against anakinra [146]. Please see full prescribing
information for complete list.
Contraindications: Serious hypersensitivity reaction to E. coli-derived proteins,
Kineret, or the inactive components [147].
3.2 Canakinumab
Canakinumab is a human monoclonal antibody against IL-1β that was first
approved by the FDA in 2009 for the treatment of cryopyrin-associated periodic
syndromes (CAPS), and, subsequently, it was approved for the treatment of SJIA
and JIA in 2013 [148, 149]. Canakinumab inhibits IL-1β by directly binding and
neutralizing IL-1β signaling. The long-term effectiveness of canakinumab as a
treatment for uveitis has not been studied. However, several case studies show
canakinumab as a potential therapeutic for refractory uveitis. Successful resolution
of inflammation with canakinumab treatment was seen in a case report of a
64-year-old patient with CAPS-associated uveitis [150]. Another case series by
Brambilla et al. (2016) showed successful treatment of refractory uveitis with
canakinumab in two children. The first patient in this study was a 9-year-old with
recurrent uveitis associated with JIA intolerant to TNF-α inhibitors and refractory
to other immune modulatory drugs. Clinical improvement was achieved within
12 months of initiating canakinumab [25]. The second patient, a 6-year-old boy
with bilateral uveitis refractory to TNF-α inhibitors, showed a faster responsiveness
with remarkable improvement to canakinumab within 2 months of treatment [25].
Another case study of a 16-year-old with severe Behcet’s disease associated refrac-
tory panuveitis, responded to a single dose of canakinumab with remission of
uveitis for at least 8 weeks [151]. Overall, the case series provides evidence of the
effectiveness of canakinumab for the treatment of uveitis. In addition, a retrospec-
tive study of 19 patients with BD-related uveitis showed an improvement of ocular
symptoms after 12 months of treatment with canakinumab [142].
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Additional prospective and retrospective studies in large patient groups are
needed to validate the effects of canakinumab in uveitis.
Administration and dosing: Canakinumab is marketed as Ilaris (Novartis, East
Hanover, NJ) and given at a dose of 150–300 mg subcutaneously every 4 weeks or
2–4 mg/kg every 4 weeks.
Adverse effects: Side effects of this drug include an increased risk of infection
[152, 153]. Please see full prescribing information for complete list.
Contraindications: Serious hypersensitivity to Ilaris or the inactive
components [154].
3.3 Gevokizumab
Gevokizumab is a humanized recombinant IgG2 monoclonal antibody with high
affinity for IL-1β. Its ability to bind strongly to IL-1β prompted interest in its use as
a biological agent for autoimmune uveitis. A prospective study of eight patients
with anterior scleritis showed improvement in symptoms in seven of the patients
following treatment with 60 mg SC of gevokizumab every 4 weeks for 12 weeks and
continued to show improvement for 36 more weeks [155].
Gul et al. conducted a prospective study to test the efficacy of gevokizumab in
patients with acute exacerbation of resistant uveitis in Behcet’s disease. Seven
adult patients were given a single intravenous gevokizumab infusion at a dose of
0.3 mg/kg. All patients experienced a rapid clinical response and resolution of
intraocular inflammation within a median duration of 14 days [156]. Gul et al. also
conducted another prospective study to test the efficacy and safety of gevokizumab
in 21 patients with Behcet’s disease-related uveitis; 3 patients were withdrawn from
the study due to exacerbation of uveitis, but 14 patients showed responsiveness
within 21 days [157]. These studies provide evidence of the effectiveness of
gevokizumab in uveitis, especially the Behcet’s-related uveitis. However, the
EYEGUARD clinical trials did not show efficacy of gevokizumab in the treatment of
uveitis [158]. In the EYEGUARD study, 83 patients with Behcet’s disease-related
uveitis were recruited into the study. Study groups were given 60 mg of
gevokizumab every 4 weeks subcutaneously and were well tolerated. However, the
results from this study did not show any treatment efficacy of gevokizumab
compared to the placebo group [158]. The conflicting results from these two studies
may be due to the route of administration with intravenous infusion being superior
to subcutaneous administration. As such, further studies on the dosage, long-term
efficacy, and safety of gevokizumab for uveitis treatment are necessary.
Administration and dosing: XOMA 052 (XOMA Corporation, Berkeley, CA, USA)
is the brand name of gevokizumab. It has not been FDA approved but in trials has
been administered at a dose of 60 mg IV or SC every 4 weeks.
Adverse effects: Gevokizumab is generally tolerated; however, it can result in mild
side effects that include injection site reaction, neutropenia, and hypoglycemia
[155, 159]. Please see full prescribing information for complete list.
Contraindications: None are listed with the FDA because it is not yet FDA
approved.
3.4 Rilonacept
Rilonacept is a fully humanized IL-1 fusion protein, and it consists of the ligand-
binding domain of the extracellular component of the IL-1 receptor and IL-1
receptor accessory protein. Rilonacept binds to IL-1β to prevent it from interacting
with IL-1 receptor, thus preventing IL-1 signaling. This drug is FDA approved for
the treatment of autoinflammatory diseases such as familial cold autoinflammatory
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syndrome (FCAS) and Muckle-Wells syndrome (MWS) [160]. However, there
are no clinical data on the use of rilonacept in uveitis, but it is currently being
evaluated as a treatment for uveitis [161].
Administration and dosing: Rilonacept is marketed as Arcalyst by Regeneron
Pharmaceuticals, Tarrytown, New York. It is given subcutaneously at a dose of two
160 mg injections at week 0 and then 160 mg/week.
Adverse effects: Local and/or hypersensitivity reaction [162, 163]. Other side
effects reported include gastrointestinal bleeding and an increased risk for Strepto-
coccus pneumoniae meningitis [160]. Please see full prescribing information for
complete list.
Some autoimmune diseases such as rheumatic diseases respond to IL-1β
inhibitors. However, the effects of these biologics in uveitis are not conclusive.
Some IL-1β inhibitors such as anakinra have demonstrated efficacy in Behcet’s
disease-related uveitis and autoinflammatory diseases such as NOMID that could
be associated with uveitis [139]. Additional large clinical studies are required to
evaluate the efficacy of IL-1β as a therapy for autoimmune uveitis.
Contraindications: None listed with the FDA [164].
4. IL-6 inhibitors
IL-6 is a powerful proinflammatory cytokine that is secreted by both innate
and adaptive immune cells (B and T cells). Due to its pleiotropic effects including
T-cell activation, IL-6 is implicated in many T-cell-mediated diseases [7]. Biologi-
cal agents that inhibit IL-6 have been used as a treatment for autoimmune
diseases such as RA and JIA. In spite of the proinflammatory effects, it has a role
in tumor survival, so blockage of IL-6 is also effective as a cancer treatment,
particularly large-cell lung cancer and ovarian cancer [165].
4.1 Tocilizumab
Tocilizumab is a fully humanized monoclonal antibody against both soluble and
membrane-bound IL-6 receptors. It is currently FDA approved for the treatment of
SJIA and RA, and it has profoundly improved disease outcomes [166]. A study by
Tappeiner et al. has reported that two out of three patients with JIA-related uveitis
responded to tocilizumab that was refractory to anti-TNF-α therapy [167].
Furthermore, a retrospective study that analyzed disease outcomes in five patients
with refractory uveitis showed sustained remission after a mean follow-up period of
8.4 months [168]. A similar outcome was observed in another study testing the
efficacy of tocilizumab to treat refractory uveitis with 10 out of 17 patients
responding to IL-6 blockade [169]. A prospective STOP-UVEITIS study to test the
safety, tolerability, and efficacy of tocilizumab in 37 patients with noninfectious
uveitis was conducted by Quan et al. (2017); the result of this study shows tolerance
at 6 months of drug initiation [170]. These studies and several case studies have
reported that tocilizumab may be effective in the treatment of refractory uveitis
[171, 172]. Also, Ruiz-Medrano et al. compiled data on the use of tocilizumab in
the treatment of ocular conditions between 2011 and 2017. They found that
tocilizumab is effective in the treatment of variety of ocular inflammatory condi-
tions including refractory uveitis [173].
Administration and dosing: Tocilizumab (Actemra, Genentech, South San
Francisco, CA, USA) is typically administered at a dose of 4–12 mg/kg every
2–4 weeks when given intravenously and 162 every 1–2 weeks when given
subcutaneously.
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Adverse effects: Side effects from Actemra include neutropenia with increased
risk of fungal and bacterial infections and opportunistic infections [174]. Other side
effects include hypersensitivity, increased risk of gastric perforation, and malig-
nancies [175–177]. Please see full prescribing information for complete list.
Contraindications: Hypersensitivity to Actemra [178]. Tuberculosis reactivation
has been reported in patients undergoing IL-6 inhibitor therapy [179], so patients
should be initially tested for latent tuberculosis and should be routinely monitored
for newly acquired tuberculosis.
Table 1.
List of biologics discussed in sections 3–6.
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4.2 Sarilumab
Sarilumab is another IL-6 receptor inhibitor, it is a fully humanized monoclonal
antibody against the alpha subunit of the IL-6 receptor, and in 2017 it was FDA
approved as a treatment for RA [180]. Sarilumab has shown some potential as an
effective therapy for autoimmune uveitis in a prospective SATURN study [181]. In
this randomized study, 57 patients with posterior uveitis on steroids with or without
methotrexate were treated with 200 mg of sarilumab or placebo every 2 weeks.
About 64% of the patients on sarilumab showed clinical improvement and steroid-
sparing effects at 16 weeks after treatment initiation [181].
Administration and dosing: Sarilumab is marketed as Kevzara (Regeneron/Sanofi
Tarrytown, NY, USA), and in the treatment of RA, sarilumab is typically given at
200 mg SC every 2 weeks.
Adverse effects: Increased risk of GI perforation and hepatitis [182]. Please see full
prescribing information for complete list.
Contraindications: Hypersensitivity to Kevzara or the inactive ingredients [183].
Tuberculosis reactivation has been reported in patients undergoing IL-6 inhibitor
therapy [179], so patients should be initially tested for latent tuberculosis and
should be routinely monitored for newly acquired tuberculosis.
Other IL-6 inhibitors: Olokizumab (UCB, Brussels, Belgium) and clazakizumab
(Alder Biopharma, Bothell, WA, USA) are currently being evaluated in clinical
trials for the treatment of autoimmune diseases (which can be associated with
uveitis) such as RA. Siltuximab (Janssen, Horsham, PA, USA) has been FDA
approved for the treatment of Castleman’s disease [184–187]. However, there are
little or no data regarding the efficacy of these drugs in uveitis. See Table 1 for
additional information regarding these drugs.
5. IL-17 inhibitors
IL-17 is a proinflammatory cytokine produced by Th17 cells, a subset of
inflammatory T cells, involved in an inflammatory response to self and certain
extracellular bacteria and fungi. While IL-17 can be produced by other cells, it is
the characteristic cytokine produced by Th17 cells. IL-17 is involved in the recruit-
ment and activation of neutrophils [188, 189]. Animal and human studies have
elucidated the critical role of IL-17 in the pathogenesis of autoimmune diseases
including uveitis [190, 191]. Inhibitors of IL-17 have produced remarkable improve-
ment in the outcome of autoimmune diseases especially rheumatoid diseases [192].
IL-17 inhibitors such as secukinumab (AIN457), ixekizumab (Taltz), and
brodalumab (AMG 827) are FDA approved for the treatment of severe psoriasis
[193]. Knowledge of the efficacies of these biological agents in autoimmune diseases
provides the potential for use in uveitis, especially uveitis that is refractory to con-
ventional drugs and other biologics. Blockade of IL-17 in animal models of autoim-
mune uveitis has produced significant improvement in uveitis symptoms [194].
5.1 Secukinumab
Secukinumab is a fully humanized monoclonal antibody that neutralizes IL-17A.
It is FDA approved for treatment of moderate to severe plaque psoriasis [195].
Hueber et al. tested the efficacy of AIN457 in a prospective study with 104 uveitis
patients, RA or psoriasis. About 50% of the uveitis patients showed a rapid response
within 2 weeks and by 8 weeks of drug initiation; 13 out of 16 patients responded to
AIN457 [196]. In a prospective study of 118 patients with Behcet’s disease (SHIELD
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study), the rate of recurrent ocular exacerbation of uveitis did not differ between
the patients that received secukinumab or placebo. The study concluded that
secukinumab did not demonstrate efficacy in the treatment of uveitis. Similar
outcomes were concluded from the INSURE and ENDURE studies in which altering
the dosing schedule of secukinumab did not improve the efficacy of secukinumab in
uveitis patients [197, 198]. The outcome of these studies may have differed from the
initial report by Hueber et al. because the differences were noted in the patient
disease profile, concomitant immunosuppressive therapies, and route of adminis-
tration [197]. One prospective study demonstrated that intravenous secukinumab
(10 mg/kg or 30 mg/kg) had better efficacy than subcutaneous secukinumab
(300 mg). Therefore, these studies demonstrate that patients responded better to
secukinumab when it was administered IV [198].
Administration and dosing: Secukinumab was initially named AIN 457 and has
been renamed Cosentyx (Novartis). It is given subcutaneously for plaque psoriasis
at a dose of 150–300 mg weekly for 4 weeks and then every 4 weeks. However, it
has been suggested that it is more effective given IV at 30 mg/kg for the treatment
of noninfectious uveitis [198].
Adverse effects: Cosentyx is associated with an increased risk of infection, hyper-
sensitivity reaction, and inflammatory bowel disease [199, 200]. Please see full
prescribing information for complete list.
Contraindications: Hypersensitivity to Cosentyx or any of the inactive ingredi-
ents [201]. Tuberculosis reactivation is listed as a warning by the FDA, but it has
been reported in a multicenter retrospective study by Novartis [202] and in a
review of the literature [203] that there is no increased risk of tuberculosis
reactivation.
Other IL-17 inhibitors: Additional biologics that target the IL-17 pathway include
ixekizumab and brodalumab. Ixekizumab targets IL-17A and is FDA approved to
treat plaque psoriasis and psoriatic arthritis. Brodalumab targets the IL-17 receptor
and is FDA approved for the treatment of plaque psoriasis. At the time of this
review, clinical trials for uveitis are underway, so there are no clinical reports
regarding their efficacy in autoimmune uveitis. See Table 1 for additional informa-
tion regarding these drugs.
6. Other biologics
Biological agents that target and inhibit cytokines such as TNF-α and IL-1β have
been extensively studied and have resulted in improving clinical outcomes in many
autoimmune diseases including uveitis. We chose to include a more in-depth
discussion of biologics that target IL-6 and IL-17 because IL-6 is such a central
inflammatory cytokine that bridges both innate and adaptive immunities, and IL-17
is the characteristic cytokine produced by Th17 T cells that are involved in autoim-
mune diseases. The efficacies of these biological agents have spurred the introduc-
tion of additional biologics that target other inflammatory mediators implicated in
autoimmunity. Also, the heterogeneity of uveitis, non-responsiveness or adverse
effects associated with the current biologics used for the treatment of uveitis, pro-
vides the need to examine the efficacy of other biological agents that target other
mediators implicated in autoimmunity. Recombinant interferon and IVIG are bio-
logics used for the treatment of refractory autoimmune uveitis and other inflam-
matory conditions [204–206]. However, the precise mechanism of action for these
medications is not well understood. Rituximab targets CD20 on B cells and is used
for the treatment of ocular cicatricial pemphigoid, scleritis, and uveitis associated
with granulomatosis with polyangiitis [207, 208]. There are also additional biologics
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that target specific cytokines and cell surface proteins that are in development and
undergoing clinical trials for autoimmune diseases that may include uveitis, rheu-
matoid arthritis, ulcerative colitis, psoriatic arthritis, and others. Since these other
biologics are still in various phases of development, we will not go into the same
level of detail as in the others discussed above. Because there are many medications
that are not public knowledge, the following is not an exhaustive list. Some of the
medications that may be available for the treatment of autoimmune uveitis in the
near future target IL-15, IL-23 p40, interferon, and its receptors, CD52, CD4,
VEGF, and VCAM. A fusion protein consisting of the B7-binding portion of CTLA4
and IgG is also available and is being evaluated for the treatment of autoimmune
uveitis.
7. Switching biological therapies
The development of multiple biologics that target specific inflammatory path-
ways has greatly increased the treatment options available for patients with auto-
immune uveitis. With so many options available, it is of interest to determine if
there is an advantage to switching the biologic, either within the same class or to a
different class. Large clinical studies have not been done with uveitis cohorts, but
some have been done with rheumatoid arthritis patients. There is some evidence
that switching biologics within the same class, specifically related to TNF-α inhibi-
tors, for reasons related to adverse reactions rather than efficacy may be beneficial
[209]. A more recent study found that switching from TNF-α inhibitors to another
biological class showed a significantly greater benefit than switching to another
TNF-α inhibitor [210]. Therefore, it is still not clear which is the best biological
treatment strategy for autoimmune uveitis patients, but there is some indication
based on RA patients that switching to a different class of biologics may have
significantly better outcomes than switching to another biological within the same
class.
8. Conclusions
In this review, we focus on biologics that target TNF-α, IL-β, IL-6, and IL-17.
The rationale for this is that TNF-α, IL-β, and IL-6 cytokines are involved in key
inflammatory pathways that target both the innate and adaptive arms of the
immune response. We also include a brief discussion of IL-17 because it is produced
by a specific T-cell subset, and Th17 cells have been demonstrated to be involved in
autoimmune diseases [190, 191]. There are other biologics that target other cyto-
kines and cell types, but these are in earlier phases of development and are not yet
FDA approved. Additional options for therapy are constantly being studied. Bio-
logics are a newer class of therapeutics that have the advantage over other medica-
tions in that they are extremely specific for one target molecule. This specificity
makes them attractive as therapeutics because specific pathways and/or cell types
can be blocked. Inhibition of a specific pathway or cell type has the advantage over
other immunosuppressive therapies that suppress all leukocytes and lymphocytes.
A drawback to biologics is the high economic burden associated with these drugs.
Because of the high cost associated with biologics, it can be difficult to obtain
insurance coverage until multiple therapies have failed. As such, the cost to the
patient could be a permanent loss of vision with repeated relapses and the use of
corticosteroids while transitioning to a new therapy. Importantly, because these
therapies have efficacy in treatment of systemic autoimmune diseases such as RA,
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inflammatory bowel diseases, and Behcet’s disease with a uveitis manifestation they
may be effective for the majority of uveitis patients that only have ocular involve-
ment [2, 211]. Therefore, additional appropriately powered clinical studies are
necessary to demonstrate the effectiveness of biologics for the treatment of chronic
autoimmune uveitis.
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CAPS cryopyrin-associated periodic syndromes
CINCA chronic infantile neurological cutaneous articular
CLL chronic lymphocytic leukemia
FCAS familial cold autoinflammatory syndrome
FDA Food and Drug Administration
FMF familial Mediterranean fever
GCA giant cell arteritis
HIDS hyperimmunoglobulin D syndrome






JIA juvenile idiopathic arthritis
MKD mevalonate kinase deficiency
MS multiple sclerosis
mTOR mammalian target of rapamycin
MWS Muckle-Wells syndrome
NHL non-Hodgkin lymphoma
NOMID neonatal-onset multisystem inflammatory disease
NSAIDs nonsteroidal anti-inflammatory drugs
PA psoriatic arthritis
PJIA polyarticular juvenile idiopathic arthritis
PP plaque psoriasis
RA rheumatoid arthritis
SJIA systemic juvenile idiopathic arthritis
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TLR toll-like receptor
TNF-a tumor necrosis factor-alpha
TRAPS tumor necrosis factor receptor-associated periodic syndrome
UC ulcerative colitis
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